News Releases

15 Mar '21
Alvotech has successfully completed a second round of its US$ 100 million private placement, for US$ 35 million. The first round which was completed in October 2020, amounted to US$ 65 million. As part of the first round Shinhan from Korea, Baxter Healthcare SA from the US and ATHOS (Strüngmann
10 Dec '20
Fuji Pharma will exclusively commercialize the medicines in Japan – discussions between the parties continue over additional biosimilar candidates Alvotech and Japanese pharmaceutical company Fuji Pharma (Tokyo Stock Exchange: 4554) announce that they have agreed on an extension on their exclusive
24 Nov '20
Through this partnership, a powerhouse has been created in one of the world’s largest biologics markets, designed to improve patient access to high quality biosimilars in China° Biosimilar candidates will be manufactured in a new Chinese biologic facility in Changchun Alvotech hf.
19 Nov '20
Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms AVT02 is highly similar to its reference product in terms of structure and function The pharmacokinetic (PK) similarity study for AVT02 (AVT02-GL-101) has met its primary
04 Nov '20
Alvotech and Cipla Medpro, a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), have entered into an exclusive partnership to bring key biosimilars to patients in emerging markets such as South Africa.
27 Oct '20
Alvotech announced today that its parent company, Alvotech Holdings SA, has successfully completed a $65 million private placement round. This has resulted in the company issuing new shares to a group of new investors and existing shareholders, which will further finance the development and release
22 Sep '20
Alvotech and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced an expansion of their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets. The initial pipeline contains biosimilar candidates addressing
12 May '20
Alvotech is developing AVT02 as a proposed biosimilar to HUMIRA® (adalimumab) with high concentration (100mg/mL) dosage forms The Phase 1 PK similarity study for AVT02 (AVT02-GL-101) has met its primary objectives The Phase 3 confirmatory efficacy and safety study for AVT02 (AVT02-GL-301) has met
Displaying 61 - 70 of 88